RESUMEN
Diabetes seriously endangers public health and brings a heavy economic burden to the country. Inflammation is one of the main inducing factors of type-2 diabetes (T2D) and may cause some complications of diabetes, such as diabetic encephalopathy and peripheral neuropathy. In-depth research and development of drugs to cure diabetes and complications are of great significance. Pueraria lobate is a medicinal herb used in several countries to treat many diseases. Here, two new polysaccharides (PLB-1-1 and PLB-1-2) were isolated and purified from the root of Pueraria lobata with molecular weights of 9.1 × 103 Da and 3.8 × 103 Da, respectively. The structure was evaluated by monosaccharide composition, GC-MS and NMR spectroscopy. It was determined that PLB-1-1 comprised â4)-α-d-Glcp-(1â, α-d-Glcp-(1â, â6)-ß-d-Galp-(1â, â3)-α-l-Araf-(1â, â3,6)-ß-d-Manp-(1â and â4,6)-ß-d-Manp-(1â, and PLB-1-2 consisted of â4)-α-d-Glcp-(1â, ß-d-Glcp-(1â, â4,6)-ß-d-Glcp-(1â, â3,6)-ß-d-Manp-(1â and α-l-Fucp-(1â. Furthermore, both PLB-1-1 and PLB-1-2 showed anti-inflammatory and inhibitory activities of α-glucosidase and α-amylase in vitro. Therefore, the new polysaccharides, i.e., PLB-1-1 and PLB-1-2, may be considered candidates for the treatment of diabetes and its related complications.